314 related articles for article (PubMed ID: 25716885)
1. Liposomal cytarabine in the prophylaxis and treatment of CNS lymphoma: toxicity analysis in a retrospective case series study conducted at Polish Lymphoma Research Group Centers.
Jurczak W; Kroll-Balcerzak R; Giebel S; Machaczka M; Giza A; Ogórka T; Fornagiel S; Rybka J; Wróbel T; Kumiega B; Skotnicki AB; Komarnicki M
Med Oncol; 2015 Apr; 32(4):90. PubMed ID: 25716885
[TBL] [Abstract][Full Text] [Related]
2. [Liposomal cytarabine in prophylaxis of the central nervous system involvement in rare aggresive lymphomas].
Kumiega B; Jurczak W; Fornagiel S; Dzietczenia J; Skotnicki AB
Przegl Lek; 2013; 70(4):187-90. PubMed ID: 23991555
[TBL] [Abstract][Full Text] [Related]
3. Central nervous system prophylaxis with intrathecal liposomal cytarabine in a subset of high-risk patients with diffuse large B-cell lymphoma receiving first line systemic therapy in a prospective trial.
González-Barca E; Canales M; Salar A; Ferreiro-Martínez JJ; Ferrer-Bordes S; García-Marco JA; Sánchez-Blanco JJ; García-Frade J; Peñalver J; Bello-López JL; Sancho JM; Caballero D;
Ann Hematol; 2016 May; 95(6):893-9. PubMed ID: 27025508
[TBL] [Abstract][Full Text] [Related]
4. Central nervous system prophylaxis with intrathecal liposomal cytarabine in diffuse large B-cell lymphomas.
Krawczyk K; Jurczak W; Długosz-Danecka M; Zauska-Giza A; Dzietczenia J; Wróbel T; Skotnicki AB
Pol Arch Med Wewn; 2013; 123(11):589-95. PubMed ID: 23928849
[TBL] [Abstract][Full Text] [Related]
5. Central nervous system involvement in T-cell lymphoma: A single center experience.
Gurion R; Mehta N; Migliacci JC; Zelenetz A; Moskowitz A; Lunning M; Moskowitz C; Hamlin P; Horwitz S
Acta Oncol; 2016 May; 55(5):561-6. PubMed ID: 27046135
[TBL] [Abstract][Full Text] [Related]
6. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
[TBL] [Abstract][Full Text] [Related]
7. Analysis of the role of intratecal liposomal cytarabine in the prophylaxis and treatment of central nervous system lymphomatosis: The Balearic Lymphoma Group experience.
García-Recio M; Cladera A; Bento L; Dominguez J; Ruiz de Gracia S; Sartori F; Del Campo R; García L; Ballester C; Gines J; Bargay J; Sampol A; Gutiérrez A
PLoS One; 2017; 12(6):e0179595. PubMed ID: 28665999
[TBL] [Abstract][Full Text] [Related]
8. Toxicity and efficacy of intrathecal liposomal cytarabine in children with leukemia/lymphoma relapsing in the central nervous system: a retrospective multicenter study.
Parasole R; Petruzziello F; Messina C; Barisone E; Pession A; Locatelli F; Micalizzi C; Cesaro S; Testi AM; De Matteo A; Varotto S; Berger M; Morello W; Menna G; Poggi V
Leuk Lymphoma; 2015 Mar; 56(3):650-5. PubMed ID: 24882262
[TBL] [Abstract][Full Text] [Related]
9. The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma.
Arkenau HT; Chong G; Cunningham D; Watkins D; Agarwal R; Sirohi B; Trumper M; Norman A; Wotherspoon A; Horwich A
Ann Oncol; 2007 Mar; 18(3):541-5. PubMed ID: 17164228
[TBL] [Abstract][Full Text] [Related]
10. Central nervous system recurrence in adult patients with acute lymphoblastic leukemia: frequency and prognosis in 467 patients without cranial irradiation for prophylaxis.
Sancho JM; Ribera JM; Oriol A; Hernandez-Rivas JM; Rivas C; Bethencourt C; Parody R; Deben G; Bello JL; Feliu E;
Cancer; 2006 Jun; 106(12):2540-6. PubMed ID: 16700036
[TBL] [Abstract][Full Text] [Related]
11. Liposomal cytarabine in prophylaxis or curative treatment of central nervous system involvement in Burkitt leukemia/lymphoma.
Segot A; Raffoux E; Lengline E; Thieblemont C; Dombret H; Boissel N; Cluzeau T
Ann Hematol; 2015 Nov; 94(11):1859-63. PubMed ID: 26280395
[TBL] [Abstract][Full Text] [Related]
12. Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era.
Ferreri AJ; Bruno-Ventre M; Donadoni G; Ponzoni M; Citterio G; Foppoli M; Vignati A; Scarfò L; Sassone M; Govi S; Caligaris-Cappio F
Br J Haematol; 2015 Mar; 168(5):654-62. PubMed ID: 25312994
[TBL] [Abstract][Full Text] [Related]
13. Randomized trial of radiation-free central nervous system prophylaxis comparing intrathecal triple therapy with liposomal cytarabine in acute lymphoblastic leukemia.
Bassan R; Masciulli A; Intermesoli T; Audisio E; Rossi G; Pogliani EM; Cassibba V; Mattei D; Romani C; Cortelezzi A; Corti C; Scattolin AM; Spinelli O; Tosi M; Parolini M; Marmont F; Borlenghi E; Fumagalli M; Cortelazzo S; Gallamini A; Marfisi RM; Oldani E; Rambaldi A
Haematologica; 2015 Jun; 100(6):786-93. PubMed ID: 25749825
[TBL] [Abstract][Full Text] [Related]
14. RD-CODOX-M/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and 'unclassifiable' highly aggressive B-cell lymphoma.
Corazzelli G; Frigeri F; Russo F; Frairia C; Arcamone M; Esposito G; De Chiara A; Morelli E; Capobianco G; Becchimanzi C; Volzone F; Saggese M; Marcacci G; De Filippi R; Vitolo U; Pinto A
Br J Haematol; 2012 Jan; 156(2):234-44. PubMed ID: 22098541
[TBL] [Abstract][Full Text] [Related]
15. Long-term survival following radiotherapy and cytarabine chemotherapy for sporadic primary central nervous system lymphoma.
Pöttgen C; Stuschke M; Stüben G; Schmitz A; Schwechheimer K; Wacker HH; Rauhut F; Kleuker S; Wilhelm H; Grehl S; Fehlings T
Strahlenther Onkol; 2003 Sep; 179(9):626-32. PubMed ID: 14628129
[TBL] [Abstract][Full Text] [Related]
16. Liposomal cytarabine is effective and tolerable in the treatment of central nervous system relapse of acute lymphoblastic leukemia and very aggressive lymphoma.
Gökbuget N; Hartog CM; Bassan R; Derigs HG; Dombret H; Greil R; Hernández-Rivas JM; Huguet F; Intermesoli T; Jourdan E; Junghanss C; Leimer L; Moreno MJ; Reichle A; Ribera J; Schmid M; Serve H; Stelljes M; Stuhlmann R; Hoelzer D;
Haematologica; 2011 Feb; 96(2):238-44. PubMed ID: 20952517
[TBL] [Abstract][Full Text] [Related]
17. Practice of central nervous system prophylaxis and treatment in acute leukemias in Spain. Prospective registry study.
Sancho JM; Morgades M; Arranz R; Fernández-Abellán P; Deben G; Alonso N; Blanes M; Rodríguez MJ; Nicolás C; Sánchez E; Fernández de Sevilla A; Conde E; Ribera JM;
Med Clin (Barc); 2008 Oct; 131(11):401-5. PubMed ID: 18928719
[TBL] [Abstract][Full Text] [Related]
18. Safety and toxicity of intrathecal liposomal cytarabine (Depocyte) in children and adolescents with recurrent or refractory brain tumors: a multi-institutional retrospective study.
Benesch M; Siegler N; Hoff Kv; Lassay L; Kropshofer G; Müller H; Sommer C; Rutkowski S; Fleischhack G; Urban C
Anticancer Drugs; 2009 Oct; 20(9):794-9. PubMed ID: 19617818
[TBL] [Abstract][Full Text] [Related]
19. Secondary central nervous system (CNS) involvement in patients with diffuse large B-cell lymphoma: a therapeutic dilemma.
Kim SJ; Oh SY; Kim JS; Kim H; Lee GW; Won JH; Shin HJ; Yang DH; Choi CW; Park J; Kim WS; Suh C
Ann Hematol; 2011 May; 90(5):539-46. PubMed ID: 20960190
[TBL] [Abstract][Full Text] [Related]
20. High Doses of Antimetabolites Followed by High-Dose Sequential Chemoimmunotherapy and Autologous Stem-Cell Transplantation in Patients With Systemic B-Cell Lymphoma and Secondary CNS Involvement: Final Results of a Multicenter Phase II Trial.
Ferreri AJ; Donadoni G; Cabras MG; Patti C; Mian M; Zambello R; Tarella C; Di Nicola M; D'Arco AM; Doa G; Bruno-Ventre M; Assanelli A; Foppoli M; Citterio G; Fanni A; Mulè A; Caligaris-Cappio F; Ciceri F
J Clin Oncol; 2015 Nov; 33(33):3903-10. PubMed ID: 26282634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
